Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies

Summary

To evaluate the safety and tolerability of multiple administration of HRS-7053 in patients with advanced malignancies Determine the maximum tolerated dose (MTD, if possible) and the recommended dose for Phase II clinical studies (RP2D)

Timeline

Start

2023-09-01

Primary completion

2025-05-30

Completion

2025-05-30

Outcome

Outcome not reported

Stopped (Business): “The sponsor's R\&D strategy is adjusted.”

Drugs

Indications